It's Time to Move Forward
Prosigna is now included in international clinical practice guidelines.
Managing patients with early-stage breast cancer begins with a highly accurate assessment of risk.
Proceed with Confidence
Prosigna uses the PAM50 gene signature to translate tumor biology into your patient's individualized prognostic score.
Advanced technology generates precise, reproducible prognostic information in local qualified laboratories.
Prosigna reliably identifies your patient's 10-year risk of distant recurrence.
Prosigna is indicated for in vitro diagnostic use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or II), or node-positive (Stage II) breast cancer to be treated with adjuvant endocrine therapy for assessment of risk of distant recurrence of disease.
Prosigna Breast
Cancer Prognostic Gene Signature Assay for use on the nCounter Dx Analysis
System is 510(k) cleared and CE-marked for in vitro diagnostic use in the
United States and EU, respectively. See Package Insert for details